| Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449) |
|---|
| 02/24/2005 | WO2005016260A2 Prodrugs for the oral and parenteral delivery of amine-containing drugs, amino acids, and peptides |
| 02/24/2005 | WO2005016258A2 Treatment of age-related macular degeneration |
| 02/24/2005 | WO2005016257A2 Process of making flowable hemostatic compositions and devices containing such compositions |
| 02/24/2005 | WO2005016256A2 Hemostatic compositions containing sterile thrombin |
| 02/24/2005 | WO2005016255A2 Substituted tetrahydroquinolines, phenylacetic acids and benzoic acids as hepatocyte nuclear factor 4 (hnf-4 ) modulator compounds |
| 02/24/2005 | WO2005016254A2 Methods and reagents for treating inflammation and fibrosis |
| 02/24/2005 | WO2005016253A2 Formula nd method for the delivery of oral medications to animals |
| 02/24/2005 | WO2005016251A2 Mutations in the cystic fibrosis gene |
| 02/24/2005 | WO2005016250A2 Cell therapy for neurometabolic disorders |
| 02/24/2005 | WO2005016249A2 Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ace inhibitor for the treatment of central nervous system damage |
| 02/24/2005 | WO2005016248A2 A novel antiproliferative factor and methods of use |
| 02/24/2005 | WO2005016247A2 Dna sequences, peptides, antibodies and vaccines for prevention and treatment of sars |
| 02/24/2005 | WO2005016246A2 Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases |
| 02/24/2005 | WO2005016245A2 Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof |
| 02/24/2005 | WO2005016244A2 Methods and compositions for the treatment of gastrointestinal disorders |
| 02/24/2005 | WO2005016243A2 Compositions of a cyclooxygenase-2 selective inhibitor and an antioxidant agent for the treatment of central nervous system disorders |
| 02/24/2005 | WO2005016241A2 Synthetic chemokine receptor ligands and methods of use thereof |
| 02/24/2005 | WO2005016240A2 Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same |
| 02/24/2005 | WO2005016239A2 Molecules enhancing dermal delivery of influenza vaccines |
| 02/24/2005 | WO2005016238A2 Severe acute respiratory syndrome |
| 02/24/2005 | WO2005016237A2 Methionine aminopeptidase and methods of use |
| 02/24/2005 | WO2005016236A2 Antibodies that immunospecifically bind to trail receptors |
| 02/24/2005 | WO2005016234A2 Compositions, methods, apparatuses, and systems for singlet oxygen delivery |
| 02/24/2005 | WO2005016232A2 Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| 02/24/2005 | WO2005016230A2 Evaluating protein signatures |
| 02/24/2005 | WO2005016229A2 Use of lipophilic diesters of chelating agent for the treatment of amyloidosis and atherosclerosis |
| 02/24/2005 | WO2005016228A2 Compositions and methods for reducing the risk of epileptic occurrence and/or for treatment of seizure disorders |
| 02/24/2005 | WO2005016227A2 Methods and pharmaceutical compositions for modulating heparanase activation and uses thereof |
| 02/24/2005 | WO2005016226A2 Pharmaceutical compositions comprising ccr5 antagonists |
| 02/24/2005 | WO2005016225A2 Stable pharmaceutical composition of rabeprazole |
| 02/24/2005 | WO2005016224A2 Novel therapeutic extracts and molecules for degenerative conditions |
| 02/24/2005 | WO2005009338A3 Method of inhibiting atf/creb and cancer cell growth and pharmaceutical compositions for same |
| 02/24/2005 | WO2005007084A3 Pancratistatin cyclic phosphate prodrugs an phenpanstatin cyclic phosphate prodrugs |
| 02/24/2005 | WO2004112708A3 Regulation of matrix metalloproteinase gene expression using specific and selective electrical and electromagnetic signals |
| 02/24/2005 | WO2004112697A3 Immune enhancing composition containing lactoferrin |
| 02/24/2005 | WO2004112688A3 7-alkyloxy-2h-1,4-benzoxacin-3(4h)-one derivatives and preparation method thereof |
| 02/24/2005 | WO2004110376A3 Ccr-2 antagonists for treatment of neuropathic pain |
| 02/24/2005 | WO2004098535A9 Modified antibodies to prostate-specific membrane antigen and uses thereof |
| 02/24/2005 | WO2004096235A8 Anti-cancer phosphonate analogs |
| 02/24/2005 | WO2004093799A3 Thyroid receptor ligands |
| 02/24/2005 | WO2004091529A3 Homogeneous, thermoreversible low viscosity polymannan gum films and soft capsules made therefrom |
| 02/24/2005 | WO2004087066A3 Hif-1 inhibitors |
| 02/24/2005 | WO2004084818A3 Measurement of estrogen activity in plants and a composition therefrom |
| 02/24/2005 | WO2004082622A3 Retinoid replacements and opsin agonists and methods for the use thereof |
| 02/24/2005 | WO2004073656A3 Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| 02/24/2005 | WO2004071424A3 Immediate release formulation of n-(2-propylpentanoyl)glycinamide |
| 02/24/2005 | WO2004071403A3 Coated particles and pharmaceutical dosage forms |
| 02/24/2005 | WO2004069181A3 Composition for the treatment of intraocular pressure |
| 02/24/2005 | WO2004055196A3 Method for identifying risk of breast cancer and treatments thereof |
| 02/24/2005 | WO2004052299A8 Modification of cyclooxygenase and lipoxygenase activity with asteridae extracts and optionally boswellic acid |
| 02/24/2005 | WO2004052293A3 Recombinant vaccine against flavivirus infection |
| 02/24/2005 | WO2004052274A3 Production of bacteriophage compositions for use in phage therapy |
| 02/24/2005 | WO2004049914A3 Methods for reacting an antigen masking compound with red blood cells with high efficiency |
| 02/24/2005 | WO2004030636A3 Human papillomavirus polypeptides and immunogenic compositions |
| 02/24/2005 | WO2004024088A3 Design of chemokine analogs for the treatment of human diseases |
| 02/24/2005 | WO2004021998A3 Gaming device and method |
| 02/24/2005 | US20050043773 Methods of improving the safety of zonisamide therapy |
| 02/24/2005 | US20050043705 Methods of using zonisamide as an adjunctive therapy for partial seizures |
| 02/24/2005 | US20050043704 Methods of using zonisamide as an adjunctive therapy for partial seizures |
| 02/24/2005 | US20050043533 Process for making alpha-substituted hydroxamic acids |
| 02/24/2005 | US20050043394 For prophylaxis and therapy of diabetes mellitus, inflammation, cancer, necrosis, gastric ulcers, neurodegenerative diseases, neuropathic diseases, neuropathic pain and polyneuropathy; free fatty acids and/or fatty acid esters and uridine, deoxyuridine, uridine monophosphate, deoxyuridine monophosphate |
| 02/24/2005 | US20050043386 2-amino-2-(ethyl or methyl)-4-{5-substituted pyrrol-2-yl}butan-1-ols, phosphates and phosphonates; antiarthritic agents; psoriasis; immunosuppressants |
| 02/24/2005 | US20050043339 Dihydropyrimidone inhibitors of calcium channel function |
| 02/24/2005 | US20050043322 For therapy of hypertension |
| 02/24/2005 | US20050043285 Formulation |
| 02/24/2005 | US20050043282 for prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases |
| 02/24/2005 | US20050043273 Compositions and methods for inhibiting slit protein and glypican interactions |
| 02/24/2005 | US20050043272 nanometer size; polysaccharide backbone linked with hydrophobic hydrocarbon group; small molecules are selected from antitumor agents, nucleic acids, peptides; renders a hydrophobic drug deliverable in a physiological fluid |
| 02/24/2005 | US20050043269 Pharmaceutically active uridine esters |
| 02/24/2005 | US20050043248 Novel lincomycin derivatives possessing antimicrobial activity |
| 02/24/2005 | US20050043223 Methods for reducing or preventing transmission of nosocomial pathogens in a health care facility |
| 02/24/2005 | US20050042741 Stenoprophiluric generation and isolation of chemical products |
| 02/24/2005 | US20050042313 Method to enhance the immune system and used for the prevention and treatment of infectious diseases |
| 02/24/2005 | US20050042294 Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions |
| 02/24/2005 | US20050042289 Tablets and methods for modified release of hydrophylic and other active agents |
| 02/24/2005 | US20050042283 Histamine and CCK2/gastrin receptor blockade in the treatment of acid-peptic disease and cancer |
| 02/24/2005 | US20050042225 Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis |
| 02/24/2005 | US20050042213 Administering rhodanine derivative and O,O*-dihydroxybenzenebis(p-amidophenol) derivative; metabolic, neurodegenerative and autoimmune diseases; wound healing, antiinflammatory, and anticarcinogenic agents; atherosclerosis, restenosis, nephropathy |
| 02/24/2005 | US20050042188 A 4-hydroxy-L-proline alkyl ester; sunscreen agents |
| 02/24/2005 | US20050042174 Consistent inhalation dry powder metered doses; concurrent delivery of bronchodilator, anticholinergic agent and antiinflammatory steroid |
| 02/24/2005 | CA2762015A1 Methods for treating cardiovascular disease using a soluble ctla4 molecule |
| 02/24/2005 | CA2535808A1 Melks as modifiers of the rac pathway and methods of use |
| 02/24/2005 | CA2535483A1 Compositions and methods for reducing the risk of epileptic occurrence and/or for treatment of seizure disorders |
| 02/24/2005 | CA2534897A1 Process of making flowable hemostatic compositions and devices containing such compositions |
| 02/24/2005 | CA2534895A1 Hemostatic compositions containing sterile thrombin |
| 02/24/2005 | CA2534777A1 Sigma-1 receptor ligand with acetylcholinesterase inhibition properties |
| 02/24/2005 | CA2534676A1 Orally administered small peptides synergize statin activity |
| 02/24/2005 | CA2534474A1 Methods for treating cardiovascular disease using a soluble ctla4 molecule |
| 02/24/2005 | CA2534298A1 Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same |
| 02/24/2005 | CA2533638A1 Arylsulfonamidobenzylic compounds |
| 02/24/2005 | CA2530803A1 A novel antiproliferative factor and methods of use |
| 02/24/2005 | CA2529307A1 Methods and compositions for the treatment of gastrointestinal disorders |
| 02/24/2005 | CA2528938A1 Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof |
| 02/24/2005 | CA2525647A1 Synthetic chemokine receptor ligands and methods of use thereof |
| 02/24/2005 | CA2525228A1 Molecules enhancing dermal delivery of influenza vaccines |
| 02/24/2005 | CA2524737A1 Antibodies that immunospecifically bind to trail receptors |
| 02/23/2005 | EP1507545A1 A terpene-based composition of substances, a method for its preparation and a method for its dispersal into the atmosphere |
| 02/23/2005 | EP1507518A1 Combination immediate release controlled release levodopa/carbidopa dosage forms |
| 02/23/2005 | EP1507504A1 Cycloalkyl inhibitors of potassium channel function |
| 02/23/2005 | CN1585772A Chemokine receptor antagonists and methods of use thereof |